Ki67 and E-cadherin Are Independent Predictors of Long-term Survival in Endometrial Carcinoma

Anticancer Res. 2023 Feb;43(2):683-687. doi: 10.21873/anticanres.16206.


Background/aim: In previous studies, we identified estrogen receptor, progesterone receptor, Ki67, p53, c-erb-B2, and E-cadherin to be individually associated with the prognosis of endometrial carcinoma. In the present study, we aimed to identify which of the aforementioned are associated with survival after long-term follow-up.

Patients and methods: A total of 106 patients were followed until their demise, or for a median of 120 months in the case of survival (range=84-240 months). At the end of the study, 38 patients had died, and 68 were alive. The association of the studied variables with survival was analyzed by means of a Weibull regression model.

Results: A final, restricted model adjusted for age, stage, and histological variety showed both Ki67 and E-cadherin to be independent predictors of a shorter and a longer survival, respectively.

Conclusion: Immunohistochemistry for Ki67 and E-cadherin is a cheap and relatively easy-to-interpret laboratory procedure for predicting survival of patients with endometrial carcinoma in clinical practice.

Keywords: E-cadherin; Endometrial carcinoma; Ki67.

MeSH terms

  • Biomarkers, Tumor
  • Cadherins / metabolism
  • Endometrial Neoplasms* / pathology
  • Female
  • Humans
  • Ki-67 Antigen / metabolism
  • Prognosis
  • Tumor Suppressor Protein p53*


  • Ki-67 Antigen
  • Tumor Suppressor Protein p53
  • Cadherins
  • Biomarkers, Tumor